Search
Searching Goglides
Loading matching companies, research, topics, and discussions.
Searching Goglides
Loading matching companies, research, topics, and discussions.
Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
Showing public results only.
Palantir just delivered the kind of quarter that makes the bull case difficult to ignore. Q2 revenue reached **$1.94 billion**, up 93% year over year. U.S. commercial revenue jumped 149%, while U.S. government revenue grew 90%. Palantir also raised its full-ye
OpenSigned-in searches appear here after you use search.
Tag facets appear after tag usage counts are rebuilt.
SEC filings, financial facts, source resources, and Goglides workspace context for Palantir Technologies Inc..
OpenPalantir's index-inclusion narrative can attract attention, but institutional flow only matters if business fundamentals keep confirming the story.
OpenPalantir is a profitable AI software company, but government contract quality matters more than headlines.
OpenPalantir reported FY2025 revenue of $4.5 billion and Q1 2026 revenue of $1.6 billion. The thesis depends on government durability, commercial AI adoption, operating leverage, customer concentration and cash conversion.
OpenAn ASML five-year double thesis focused on EUV scarcity, High-NA adoption, China/export-control risk, bookings visibility, and semiconductor capex cycles.
OpenA Coverage Bootstrap ASML company evaluation covering the business model, EUV and DUV products, customers, moat, financial quality, export-control risk, valuation setup, and watchlist triggers.
OpenAgomAb Therapeutics is a newly public clinical-stage fibrosis biotech with no revenue, a Nasdaq ADS listing, an IPO-funded runway into the first half of 2029, and two 2026 data tracks that need to validate organ-restricted ALK5 inhibition.
OpenTag facets appear after tag usage counts are rebuilt.